Evidence map›Paper›PMID 35987926›Full record

ArticleJournal of cancer research and clinical oncology2023

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study.

Song-Yau Wang, Tanja Holzhey, Simone Heyn, Thomas Zehrfeld, Susann Fricke, Franz Albert Hoffmann, Cornelia Becker, Leanthe Braunert, Thomas Edelmann, Inessa Paulenz and 15 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 1 country.

Song-Yau WangHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, University of Leipzig, Liebigstraße 22, 04103, Leipzig, Germany. Song-Yau.Wang@medizin.uni-leipzig.de.ORCID http://orcid.org/0000-0001-5433-8750
Tanja HolzheyHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, University of Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Simone HeynHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, University of Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Thomas ZehrfeldHospital Torgau, Christianistraße 1, 04860, Torgau, Germany.
Susann FrickeHospital Torgau, Christianistraße 1, 04860, Torgau, Germany.
Franz Albert HoffmannHematology Practice, Biedermannstraße 84, 04277, Leipzig, Germany.
Cornelia BeckerHematology Practice, Biedermannstraße 84, 04277, Leipzig, Germany.
Leanthe BraunertHematology Practice, Theodor - Heuss-Str. 2, 04435, Schkeuditz, Germany.
Thomas EdelmannHematology Practice, Theodor - Heuss-Str. 2, 04435, Schkeuditz, Germany.
Inessa PaulenzHospital Dessau, Auenweg 38, 06847, Dessau-Roßlau, Germany.
Marcus HitzschkeHospital Borna, Rudolf-Virchow-Straße 2, 04552, Borna, Germany.
Franziska FladeHematology Practice, Strümpellstraße 42, 04289, Leipzig, Germany.
Andreas SchwarzerHematology Practice, Strümpellstraße 42, 04289, Leipzig, Germany.
Klaus FenchelHematology Practice, Bahnhofstraße 12, 07318, Saalfeld, Saale, Germany.
Georg-Nikolaus FrankeHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, University of Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Vladan VucinicHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, University of Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Madlen JentzschHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, University of Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Sebastian SchwindHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, University of Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Saskia HellHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, University of Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Donata BackhausHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, University of Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Thoralf LangeHospital Weißenfels, Naumburger Straße 76, 06667, Weißenfels, Germany.
Dietger NiederwieserHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, University of Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Markus ScholzInstitute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Härtelstraße 16‑18, 04107, Leipzig, Germany.
Uwe PlatzbeckerHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, University of Leipzig, Liebigstraße 22, 04103, Leipzig, Germany.
Wolfram PönischHematology and Cell Therapy, Medical Clinic and Policlinic 1, University Hospital Leipzig, University of Leipzig, Liebigstraße 22, 04103, Leipzig, Germany. Wolfram.Poenisch@medizin.uni-leipzig.de.
University Hospital Leipzig · DEAsklepios Klinik Weißenfels · DEStädtisches Klinikum Dessau · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAutologous stem cell transplantation (ASCT) is the standard treatment for younger patients with newly diagnosed multiple myeloma (MM). However, due to restrictive exclusion criteria, more than half of eligible patients are usually excluded from transplant studies.

methodsThis retrospective monocentric analysis included 540 patients with MM who received an ASCT between 1996 and 2019.

resultsUp to 2005, induction therapy consisted mainly of conventional chemotherapies, e.g. vincristine/doxorubicin/dexamethasone (VAD). In the following years, the triple-combinations based on bortezomib coupled with doxorubicin/dexamethasone (PAD), melphalan/prednisolone (VMP), cyclophposphamide/dexamethasone (VCD) or bendamustine/prednisolone (BPV) became the most popular treatment options. A progressive improvement in PFS was observed in patients treated with the two current induction therapies BPV (47 months) or VCD (54 months) compared to VAD (35 months, p < 0.03), PAD (39 months, p < 0.01 and VMP (36 months, p < 0.01). However, there was no significant difference in median OS (VAD 78, PAD 74, VMP 72, BPV 80 months and VCD not reached). In our analysis, we also included 139 patients who do fulfill at least one of the exclusion criteria for most phase 3 transplant studies (POEMS/amyloidosis/plasma cell leukemia, eGFR < 40 mL/min, severe cardiac dysfunction or poor general condition). Outcome for these patients was not significantly inferior compared to patients who met the inclusion criteria for most of the transplant studies with PFS of 36 vs 41 months (p = 0.78) and OS of 78 vs 79 months (p = 0.34).

conclusionsOur real-world data in unselected pts also stress the substantial value of ASCT during the first-line treatment of younger MM pts.

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDoxorubicinHumansInduction ChemotherapyPrednisoloneRetrospective StudiesTransplantation, AutologousBortezomibDexamethasoneDoxorubicinPrednisoloneAutologous stem cell transplantationBortezomibMultiple myelomaReal-world evidence

Identifiers

PMID35987926
PMCPMC10314844
OpenAlexW4292440641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.